C-MGFMTNF Pharmaceuticals (was MyMD)
biotech pharmaceuticals, MYMD-1, Supera-CBD
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MGFM
C-MGFMC-MGFMbiotech pharmaceuticals, MYMD-1, Supera-CBD
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and pharmacokinetic properties. The study data will guide the establishment of an optimum therapeutic dose.
The proposed study will establish a newly-identified signaling pathway regulating both autophagy and apoptosis in human satellite cells. These findings will allow for novel pharmacological targets in satellite cells to return regenerative capacity to elderly individuals. Up to 80 adults, 21 years of age and greater, will undergo a consent visit followed by three blood draws and muscle biopsy visits- baseline (pre), after the first exercise bout (post-acute), and after the 12 week training program (post-chronic). Blood will be obtained and tested for inflammatory (IL-6/TNF/IL-1) and endocrine markers (Testosterone/Estrogen/Thyroid hormone). As part of the intervention, participants will undergo moderate intensity treadmill exercise three times per week for 10-12 weeks or serve as sedentary controls. Muscle stem cell function will be compared across age groups at each time point using a One Way ANOVA or t test for specific comparisons. An alternative analysis will be a longitudinal design following muscle stem cell function from each individual before and after exercise training. This analysis will be performed with repeated measure ANOVAs. Data will be analyzed using GraphPad Prism 6 statistical software. Significance will be accepted as p\<.05. Thigh Muscle biopsies may result in momentary pain and discomfort, burning or bleeding, numbness, and rarely fainting or infection. The incision site may leave a scar and muscle soreness may be present up to ten days after the biopsy. While the local numbing medicine xylocaine is almost entirely free from allergic properties (such as causing hives), an allergic reaction is possible, and the participant will not be given xylocaine if they have a history of such a reaction. The xylocaine will be given by a small injection into the skin at the site of the muscle biopsy. Risks associated with a standard blood draw include momentary discomfort and/or bruising. In addition, there is a minimal risk of infection, excess bleeding, clotting, and fainting. An exercise program may result in muscle, bone and/or joint soreness, discomfort and/or injury. All collected data will be stored in a locked file to be accessed only by Dr. White and his study staff. Study records that identify subjects will be kept confidential as required by law.
Double-blind, placebo-controlled, First-in-Human, single ascending-dose study. Approximately 40 healthy adult male subjects will be given a single capsule of MYMD1 to determine its safety, how well it is tolerated, how the body acts on the experimental drug, and how the experimental drug acts on the body. This will be based on blood and urine sample analysis and other physical measurements.
TNFA Stock Price and TNF Pharmaceuticals Guide Bitget App Trade smarter Buy crypto Markets Trade Futures Earn Square More daily_trading_volume_value market_share 58.45 % Current ETH GAS: 0.1-1 gwei Hot BTC ETF: IBIT Bitcoin Rainbow Chart : Accumulate Bitcoin halving: 4th in 2024, 5th in 2028 BTC/USDT $ ( 0.00 %) index 18(extreme_fear) banner.title : 0 (index.bitcoin) coin_price.total_bitcoin_net_flow_value0 new_user claim_now download_app download_now daily_trading_volume_value market_share 58.45 % Current ETH GAS: 0.1-1 gwei Hot BTC ETF: IBIT Bitcoin Rainbow Chart : Accumulate Bitcoin halving … Bitget Blog Bitget Token (BGB) Announcement Center Proof of Reserves Protection Fund Bitget UEX Partner links LALIGA partnership MotoGP partnership Blockchain4Youth Blockchain4Her Sitemap Products Spot Futures TradFi Onchain Stocks Convert & Block Trade Margin Earn Spot copy trading Futures copy trading Bot copy trading Bots APIs TraderPro Web3 wallet Fiat OTC Bitget Swap Telegram Apps Center Discord Apps Center Airdrop library Stock markets Gold price today Silver price … Pi Network price ADA price Solana price Trump coin price Dogecoin price Support Submit feedback Help Center Verify official channels Anti-scam hub Listing application VIP services Affiliate program Institutional services Asset custody Download data Promotions Referral program Fee schedule Tax filing API Legal Service Agreement Law enforcement request Regulatory request Compliance Regulatory license AML/CFT policies Privacy policy Terms of Service Risk disclosure Scan to downl
BioPharma Clinical Trial Results | MyMD Pharmaceuticals® Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals Clinical Trials Strategic positioning for clinical trial results in 1Q 2022 TNF Pharmaceuticals has received FDA clearance to commence a Phase 2 clinical trial of MYMD-1 ® in Sarcopenia (aging) in 2021 and expects efficacy data by the end of first quarter of 2022 . In addition, we expect to advance MYMD-1 ® into a p … tudies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders. We’re making news in the biotech pharmaceuticals industry TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “
isomyosamine (MYMD-1) / TNF Pharmaceuticals, Bascom Palmer Eye Institute isomyosamine (MYMD-1) / TNF Pharmaceuticals, Bascom Palmer Eye Institute - LARVOL DELTA Home Next Prev 1 to 25 Of 35 Go to page 1 2 June 24, 2025 TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease (Businesswire) - "TNF Pharmaceuticals, Inc...announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease D … Pharmaceuticals, Inc...announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1 as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024....Under this IND, the Phase 2 clinical trial of MYMD-1 will be a randomized placebo-controlled study that is expected to enroll approximately 60 patients with a … ious August 14, 2023 FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1 in Rheumatoid Arthritis (RA) (Businesswire) - "MyMD Pharmaceuticals, Inc...announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug Application (IND) to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF-α inhibitor MYMD-1® in pati … alpha; inhibitor MYMD-1® in patients with active rheumatoid arthritis (RA). The application was based on preclinical data showing that MYMD-1 significantly reduced swelling and other clinical arthritis measures compared to widely used RA therapy, Enbrel® (etanercept). The Company plans to initiate discussions with CRO vendor IQVIA on timing of a Phase 2 study in this indication." IND • New P2 trial • Immunology • Rheumatoid Arthritis Print Email More sharing Reddit StumbleUpo
TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis Skip to main content Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trend … NF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS Terms SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including t … be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page . Read our full terms of servi … 2,000% run and has identified the top... InvestorPlace | Sponsored The $15 Gold Fund That Pays Up to $1,152/Month Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying... Investors Alley | Sponsored Do NOT Buy SpaceX – Do This Instead SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul... Stansberry Research | Sponsored Are we ignoring the same signal Wall Stree … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured By Empowering Individual Investors 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 [email protected] (844) 978-6257 Twitter Facebook YouTube LinkedIn Instagram TikTok About MarketBeat About Editorial Guidelines Authors Press Room Careers Contac
Buy TNF Pharmaceuticals Inc Stock – TNFA Stock Quote Today & Investment Insights - Public.com Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started TNF Pharmaceuticals Inc TNFA is now QCLS This stock has changed its ticker name. This happens for a variety of reason, including a corporate merger or simply a change in company name. Learn More Go to the new stock page TNFA Stock News View all Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS” Business Wire • 09/25 … r iOS or Android. 2 Add funds to your Public account There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer. 3 Choose how much you'd like to invest in TNFA stock Navigate to the Explore page. Then, type TNFA into the search bar. When you see TNFA stock appear in the results, tap it to open up the purchase screen. 4 Manage your investments in one place You can find your newly purchased TNFA st … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i
false FY 0001321834 8482891 P5Y P10Y P5Y P10Y P10Y P5Y 0001321834 2023-01-01 2023-12-31 0001321834 2023-06-30 0001321834 2024-03-29 0001321834 2023-12-31 0001321834 2022-12-31 0001321834 us-gaap:RelatedPartyMember 2023-12-31 0001321834 us-gaap:RelatedPartyMember 2022-12-31 0001321834 MYMD:SeriesFConvertiblePreferredStockMember 2023-12-31 0001321834 MYMD:SeriesFConvertiblePreferredStockMember 2022-12-31 0001321834 MYMD:SeriesDConvertiblePreferredStockMember 2023-12-31 0001321834 MYMD:SeriesDConvertiblePreferredStockMember 2022-12-31 0001321834 MYMD:SeriesFConvertiblePreferredStockMember 2023-01 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of “large accelerated filer,” “accelerated filer, “smaller reporting company” and “emerging growth company” … he patent term is 20 years from the date of filing of the first non-provisional application in which priority is claimed. In the U.S. patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extensi … in, expensive, and it typically takes many years to generate sufficient data to apply for approval, even when such approval is not ultimately granted, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.   Pre-clinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the produc … bstantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $4 million for fiscal year 2024 and $3.2 million for fiscal year 2023 (for applications containing clinical data), which increased from $3.1 million for fiscal year 2022. Fee waivers or reductions are available in certain circ
In the Pipeline - Anti-Aging Solutions | TNF Pharmaceuticals Biotech Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals New approaches to combat aging and treat autoimmune diseases Our Pipeline TNF Pharmaceuticals has assembled a compelling portfolio of drug candidates to regulate the immunometabolic response through well-defined and efficient clinical pathways. We are using pre-clinical and clinical longevity research an … tudies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, chronic pain, and anxiety disorders. Our drug candidates TNF Pharmaceuticals is using pre-clinical and clinical longevity research and studies to explore the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety and sleep disorders. MYMD-1 ® MYMD-1® is an orally available,
TNF Pharmaceuticals | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas TNF Pharmaceuticals Website: TNF Pharmaceuticals Business Area(s) Therapeutics Description TNF Pharmaceuticals has assembled a compelling portfolio of drug candidates to regulate the immunometabolic response through well-defined and efficient clinical pathways. Company Location(s) West Dept
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty July 31, 2023 | 7 min read Twitter LinkedIn Facebook Email Print MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Data Planning and Database Lock - TNF Pharmaceuticals Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals Data Planning and Database Lock July 11, 2023 Jenna Brager, PhD, RN, MS Executive Vice President of Drug Development for MyMD Pharmaceuticals, Inc. Data is the most important asset for a pharmaceutical or biotechnology company to produce during clinical development1. Ensuring the highest quality data in a clinical tria
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs December 20, 2024 | 7 min read Twitter LinkedIn Facebook Email Print Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated wi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biotech Research - The Latest Insights and Reports | MyMD Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals Groundbreaking biotech research on first-in-class drug therapies Developing better treatments for patients in need At TNF Pharmaceuticals ® , we’re partnering with internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that
Technology Networks: Eliciting the Hormetic Effect: The Importance of Plant Alkaloids for Treatment of Inflammation - TNF Pharmaceuticals Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals Technology Networks: Eliciting the Hormetic Effect: The Importance of Plant Alkaloids for Treatment of Inflammation February 15, 2021 Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation,
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. - TNF Pharmaceuticals Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. July 22, 2024 New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inh
Leading the Charge in Biotech Pharmaceuticals | TNF Pharmaceuticals Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications Press Release September 02, 2025 9:15am EDT NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has e
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
TNF Pharmaceuticals, Inc. SEC 10-K Report — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / TNF Pharmaceuticals, Inc. SEC 10-K Report TNF Pharmaceuticals, Inc. SEC 10-K Report 4 min read TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on extending healthy lifespan through the development and commercialization of therapeutic platforms, has released its Form 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challen
SC 13D 1 hjw1.htm CUSIP No. 62856X102 Page 1 of 7 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MYMD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 62856X102 (CUSIP Number) Samuel Duffey 8771 Grey Oaks Ave. Sarasota, Florida 34238  941-400-4788 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 7, 2022 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a stat
When did MyMD announce its merger with Akers Biosciences? - TNF Pharmaceuticals Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals When did MyMD announce its merger with Akers Biosciences? February 7, 2021 Back to All News MyMD announced the merger on November 10, 2020. Akers entered into a definitive merger agreement with MyMD. Upon closing the transaction, the combined company will be named MyMD Pharmaceuticals ® , Inc.
Biopharma News & Media | MyMD Welcome to TNF Pharmaceuticals (formerly MyMD Pharmaceuticals) Contact TNF Pharmaceuticals About Us Lekarna Maribor SI Pipeline MYMD-1 ® Supera-CBD Research Clinical Trials Investors News Subscribe Contact TNF Pharmaceuticals Making strides in the treatment of chronic disease Biopharma news and perspectives from TNF Pharmaceuticals Stay up-to-date on our latest thought leadership, as well as pharmaceutical industry trends and news. Select News Category All Resources News Perspectives Press Releases Thought Leadership TNF Pharmaceuticals Featured in the
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
TNF Pharmaceuticals to initiate Phase II clinical trials of MYMD-1 Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manuf … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025 April 16, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly pat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development April 22, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Machine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment BALTIMORE--(BUSINESS WIRE)-- $TNFA --TNF Ph … pies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management. In keeping with FDA’s recent draft Guidance on using Artificial Intelligence, the TNF-Renova partnership is analyzing data from 30,000 patients to identif … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia March 17, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therap … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion January 15, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 March 5, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated w … sociated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., Pre … ipant Dial-In: 877-407-0832 / +1 201-689-8433 Live Webcast: Join here . Q&A Submit questions to [email protected] prior to the event 30-day phone replay: 877-660-6853 / 201-612-7415; Access ID: 13752199 30-day webcast replay: Same link above. About Isomyosamine Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell sign … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min re
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference December 9, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia st … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Develo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists May 8, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Use of AI and machine learning accelerates identification of patient groups whose ca … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor February 26, 2025 | 8 min read Twitter LinkedIn Facebook Email Print Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin